Table 1 Baseline characteristics
From: HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial
Vaccine groups | Placebo group | All | |||||||
|---|---|---|---|---|---|---|---|---|---|
16 µg (n = 24) | 32 µg (n = 25) | 64 µg (n = 23) | Placebo (n = 14) | ||||||
CD4 < 350 | CD4 ≥ 350 | CD4 < 350 | CD4 ≥ 350 | CD4 < 350 | CD4 ≥ 350 | CD4 < 350 | CD4 ≥ 350 | ||
N | 14 | 10 | 9 | 16 | 8 | 15 | 6 | 8 | 86 |
% Men | 10 (71.4) | 9 (90.0) | 7 (77.8) | 12 (75.3) | 7 (87.5) | 14 (93.3) | 4 (66.7) | 5 (62.5) | 68 (79.1) |
White race, % | 7 (50.0) | 7 (70.0) | 5 (55.6) | 8 (50.0) | 6 (75.0) | 11 (73.3) | 4 (66.7) | 4 (50.0) | 52 (60.5) |
Age (years) | 44 (39–50) | 48 (43–51) | 48 (42–51) | 48 (42–51) | 54 (42–55) | 47 (43–54) | 55 (46–56) | 50 (43–53) | 48 (42–54) |
HIV duration (years) | 7.5 (5.0–13.1) | 16.6 (6.4–24.6) | 10.1 (5.5–15.9) | 10.6 (7.9–23.3) | 7.1 (3.7–19.4) | 15.3 (10.9–20.6) | 25.7 (5.7–27.7) | 12.4 (5.1–20.6) | 11.9 (5.5–22.1) |
cART duration (years) | 7.4 (4.4–26.1) | 13.4 (2.3–18.5) | 8.2 (4.1–21.7) | 9.3 (6.9–16.1) | 6.3 (3.2–13.3) | 12.7 (7.4–19.6) | 8.6 (3.2–23.1) | 10.2 (4.9–24.9) | 9.3 (5.1–17.8) |
Nadir CD4 count (c/mm3) | 133 (75–170) | 170 (88–232) | 160 (140–171) | 168 (81–238) | 124 (86–172) | 199 (106–246) | 85 (64–122) | 244 (166–305) | 159 (90–213) |
CD4 count (c/mm3) | 269 (249–301) | 444 (412–481) | 280 (267–307) | 415 (396–435) | 306 (286–327) | 410 (364–464) | 289 (257–33) | 415 (369–434) | 364 (300–426) |
% CD4 | 22.9 (17.0–28.5) | 29.8 (27.5–37.2) | 24.2 (22.5–28.5) | 27.0 (22.9–33.0) | 26.2 (18.0–36.6) | 25.5 (21.5–32.0) | 22.5 (21.5–31.0) | 30.8 (27.8–35.0) | 27.1 (19.8–32.2) |
CD4/CD8 ratio | 0.50 (035–0.77) | 0.85 (0.58–1.07) | 0.58 (0.47–0.90) | 0.65 (0.54–1.04) | 0.47 (0.40–0.91) | 0.59 (0.36–0.83) | 0.46 (0.37–0.65) | 0.78 (0.66–0.93) | 0.62 (0.40–0.91) |
HIV DNA (copies/106 PBMC) | 841 (603–1122) | 602 (398–872) | 649 (306–1004) | 739 (422–929) | 786 (384–1113) | 691 (259–1463) | 1403 (426–2369) | 347 (191–985) | 738 (384–1088) |
